Clinicopathological and prognostic significance of HER2-low expression in advanced gastric cancer: a retrospective observational study
Authors:
- Yukiya NaritaYNYukiya Narita
- Taro MizunoTMTaro Mizuno
- Yasunobu IshizukaYIYasunobu Ishizuka
- Tomoki SakakidaTSTomoki Sakakida
- Toshiki MasuishiTMToshiki Masuishi
- Hiroya TaniguchiHTHiroya Taniguchi
- Shigenori KadowakiSKShigenori Kadowaki
- Kazunori HondaKHKazunori Honda
- Masashi AndoMAMasashi Ando
- Masahiro TajikaMTMasahiro Tajika
- Daisuke TakahariDTDaisuke Takahari
- Kei MuroKMKei Muro
Open Access
- 2 December 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (7)
Abstract
Purpose: Human epidermal growth factor receptor 2 (HER2) status is a critical biomarker in advanced gastric cancer (AGC). While the role of HER2-positive tumors in guiding targeted therapies is well-established, the clinical implications of HER2-low expression, defined as immunohistochemistry (IHC) 1+ or IHC 2+/in situ hybridization-negative (ISH-negative), remain undetermined. The aim of this study was to investigate the prognostic significance and clinicopathological features of HER2-low AGC. Patients and methods: This retrospective analysis involved patients with AGC treated with first-line fluoropyrimidine and platinum-based chemotherapy from 2011 to 2020. Patients were categorized into HER2-zero (HER2 IHC 0), HER2-low (IHC 1+ or 2+/ISH-negative), and HER2-positive (IHC 2+/ISH-positive or 3+) groups. Results: Among 548 patients analyzed, 33.0%, 45.1%, and 21.8% were classified as HER2-zero, HER2-low, and HER2-positive, respectively. The proportions of male patients, intestinal-type histology, esophagogastric junction/cardia involvement, metastatic disease status, ≥2 metastatic sites, liver metastasis, lymph node metastasis, and high serum carcinoembryonic antigen levels were gradually elevated in the HER2-zero, HER2-low, and HER2-positive groups. Overall survival (median) was 13.8, 13.6, and 23.0 months, respectively, with a non-significant trend favoring HER2-positive over HER2-low (adjusted hazard ratio: 0.80; P = .0672). A delayed separation of Kaplan-Meier curves for overall survival between the HER2-zero and HER2-low groups was observed, without reaching statistical significance (adjusted hazard ratio: 1.12; P = .2568). Conclusion: Patients with HER2-low status exhibited intermediate and specific clinicopathological features within the HER2-negative category. In terms of prognosis, HER2-low patients showed a worsening trend compared with HER2-positive patients. This evidence implies that HER2-low status represents a distinct clinical subset, bridging the gap between the HER2-zero and HER2-positive profiles.Keywords
This publication has 26 references indexed in Scilit:
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancerESMO Open, 2024
- Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinomaESMO Open, 2023
- Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trialThe Lancet, 2023
- Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition)Gastric Cancer, 2022
- Prognostic Factors in Patients with Advanced HER2-Positive Gastric Cancer Treated with Trastuzumab-Based Chemotherapy: a Cohort StudyJournal of Gastrointestinal Cancer, 2022
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialThe Lancet, 2021
- HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancerGastric Cancer, 2014
- Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese populationGastric Cancer, 2013
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009